Edgewise Therapeutics
Megan McNeill is currently working as an Associate Director Clinical Operations. Megan has a strong background in clinical research and program coordination, having gained experience in various roles in the healthcare and research sectors. Megan has been involved in managing clinical trials, coordinating research studies, and providing support in healthcare settings. With a solid educational foundation in health-related fields, Megan brings a wealth of knowledge and expertise to their current role.
This person is not in any offices
Edgewise Therapeutics
1 followers
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.